Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
S V Badve, Sunil V. Badve, Vlado Perkovic, Vivekanand Jha et autres
Importance: Approximately 10% to 15% of patients with advanced chronic kidney disease (CKD) experience a fatal or nonfatal cardiovascular event annually. The effects of antithrombotic therapies on cardiovascular events in patients with advanced CKD are unknown. Objective: To determine whether low-dose rivaroxaban …
au, us, in, gb, my, de, be, fr, mc, sa, Tunisie, ca, sg, cn, nl, nz (code pays fourni par la source)
3 citations
JAMA